SUPN Q4 2017 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$88M+41.8% YoY

Gross Profit

$84M95.3% margin

Operating Income

$34M38.8% margin

Net Income

$14M15.4% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$36M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$424M

Total Liabilities

$157M

Stockholders' Equity

$267M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$88M	$62M	+41.8%
Gross Profit	$84M	$59M	+43.8%
Operating Income	$34M	$16M	+110.8%
Net Income	$14M	$14M	-4.6%